" class="no-js "lang="en-US"> RQM+ Appoints Steven Pilewski as Lab Services COO
Friday, May 24, 2024

RQM+ Appoints Steven Pilewski as Lab Services Chief Operating Officer

RQM+, the world’s leading MedTech service provider, has announced the appointment of Steven Pilewski as Chief Operating Officer for its lab services business unit, which provides chemical characterization and complex product deformulation, as well as contaminant and failure investigations, to MedTech manufacturers. The business unit was founded more than 40 years ago as Jordi Labs, which was acquired by RQM+ in September 2022.

With more than 30 years of MedTech and pharma expertise, Pilewski most recently served as vice president of PPD Laboratories’ Good Manufacturing Practices (GMP) lab, which is a division of Thermo Fisher Scientific. When he began his career at PPD 24 years ago, the GMP lab was a small business with only 50 employees. During his tenure as a member of the executive leadership team, Pilewski continued to drive the business unit’s global organic growth strategy, transforming it into a leading global analytical services enterprise with more than 3,000 people.

“Steven is an excellent fit to lead our lab services business,” said RQM+ CEO Margaret Keegan. “His experience will help us achieve our growth goals – expanding capacity to better serve our clients, broadening our geographic reach, and innovating to develop new ways to support medical device and diagnostics manufacturers. His deep expertise with extractables and leachables and device testing, which serves as a key differentiator for us, will also help further our reputation as a leader in polymers, quantitation and eliminating unknowns.”

In addition to his leadership experience at both public and private equity owned companies, Pilewski has a master’s degree in pharmaceutical and medical device law and intellectual property from Seton Hall University. He also has a bachelor’s degree in chemistry from the College of New Jersey.

Mark Jordi, formerly president of Jordi Labs, is transitioning to an advisory role and will continue supporting RQM+.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more